Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification.
Dufault SM, Davies GR, Svensson EM, Sloan DJ, McCallum AD, Patel A, Van Brantegem P, Denti P, Phillips PPJ. Dufault SM, et al. Among authors: phillips ppj. medRxiv [Preprint]. 2024 May 7:2024.05.06.24306879. doi: 10.1101/2024.05.06.24306879. medRxiv. 2024. Update in: Int J Antimicrob Agents. 2024 Dec 7:107404. doi: 10.1016/j.ijantimicag.2024.107404 PMID: 38766235 Free PMC article. Updated. Preprint.
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R. Svensson EM, et al. Among authors: phillips ppj. Clin Infect Dis. 2018 Jun 18;67(1):34-41. doi: 10.1093/cid/ciy026. Clin Infect Dis. 2018. PMID: 29917079 Free PMC article.
Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay.
Sabiiti W, Azam K, Farmer ECW, Kuchaka D, Mtafya B, Bowness R, Oravcova K, Honeyborne I, Evangelopoulos D, McHugh TD, Khosa C, Rachow A, Heinrich N, Kampira E, Davies G, Bhatt N, Ntinginya EN, Viegas S, Jani I, Kamdolozi M, Mdolo A, Khonga M, Boeree MJ, Phillips PPJ, Sloan D, Hoelscher M, Kibiki G, Gillespie SH. Sabiiti W, et al. Among authors: phillips ppj. Thorax. 2020 Jul;75(7):606-608. doi: 10.1136/thoraxjnl-2019-214238. Epub 2020 Apr 30. Thorax. 2020. PMID: 32354738 Free PMC article.
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.
Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ; PanACEA Consortium. Te Brake LHM, et al. Among authors: phillips ppj. Eur Respir J. 2021 Jul 8;58(1):2000955. doi: 10.1183/13993003.00955-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33542056 Free PMC article.
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.
Musisi E, Wyness A, Eldirdiri S, Dombay E, Mtafya B, Ntinginya NE, Heinrich N, Kibiki GS, Hoelscher M, Boeree M, Aarnoutse R, Gillespie SH, Sabiiti W; PanACEA consortium. Musisi E, et al. Lancet Microbe. 2023 Nov;4(11):e913-e922. doi: 10.1016/S2666-5247(23)00191-X. Epub 2023 Oct 10. Lancet Microbe. 2023. PMID: 37832571 Free article.
132 results